Fig 2.

Kaplan-Meier analyses of the impacts of BRAF V600E or TERT C288T alone or their coexistence on disease-free survival of patients with papillary thyroid cancer (PTC). (A) Results of the analyses of patients with PTC of all types. (B) Results of the analyses of conventional variant PTC only. Four groups of patients are indicated in A and B, including patients with neither mutation (gray lines), TERT C228T mutation only (gold lines), BRAF V600E mutation only (blue lines), and coexistence of the two mutations (red lines).